相关实验视频

Updated: Jun 14, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

临床医生对单一中心每天一次给B细胞恶性瘤服用赞努布鲁丁尼布的观点

Mohit Narang¹, Courtney Horn¹, Edward Lee¹

¹US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA.

Clinical Medicine Insights. Oncology

|September 6, 2024

概括

赞努布鲁丁尼布是一种布鲁顿氨酸激酶抑制剂,在每天一次 (QD) 和每天两次 (BID) 的剂量中,对于B细胞恶性瘤,提供了类似的疗效和安全性. 临床医生的经验表明,QD剂量可以改善坚持和减少患者负担.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
血液学血液学血液学

背景情况:

赞努布鲁丁尼布是B细胞恶性瘤的经批准的布鲁顿氨酸激酶抑制剂.
它可提供每天两次160毫克 (BID) 和每天一次320毫克 (QD) 方案.
这两种疗法都显示出类似的疗效和安全性.

研究的目的:

探索临床医生对扎努布鲁丁尼布剂量模式的看法.
为了比较QD的现实实践模式与ZANUBRUTINIB的两天两天的管理.
在特定患者群体中确定QD剂量的潜在益处.

主要方法:

采访了两个临床护理专业人员在一个瘤中心.
讨论的重点是关于扎努布鲁丁尼布QD与WM和慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 的两次剂量的经验.

主要成果:

一些医生和药剂师更喜欢QD疗法.
相比于两次剂量,QD剂量可能会提高治疗坚持度.
患者报告了QD剂量的积极经验,包括减少了给药负担,特别是那些使用多种药物的患者.

结论:

赞努布鲁丁尼布QD疗法可能为WM或CLL/SLL患者提供优势.
QD剂量可以使患者和临床护理团队都受益,因为它可以改善患者的坚持和简化治疗.
建议在接受扎努布鲁丁尼布的患者考虑QD治疗方案.

关键词:

沃尔登斯特罗姆的巨型球蛋白血症赞努布鲁丁尼布 (Zanubrutinib) 是一种可以慢性淋巴细胞白血病慢性淋巴细胞白血病剂量表剂量表现实世界的真实世界.小型淋巴细胞淋巴瘤.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...